529 related articles for article (PubMed ID: 7964616)
21. Simultaneous detection of the two main proliferation driving EBV encoded proteins, EBNA-2 and LMP-1 in single B cells.
Rasul AE; Nagy N; Sohlberg E; Ádori M; Claesson HE; Klein G; Klein E
J Immunol Methods; 2012 Nov; 385(1-2):60-70. PubMed ID: 22921685
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.
Deacon EM; Pallesen G; Niedobitek G; Crocker J; Brooks L; Rickinson AB; Young LS
J Exp Med; 1993 Feb; 177(2):339-49. PubMed ID: 8381153
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
Wang F; Gregory C; Sample C; Rowe M; Liebowitz D; Murray R; Rickinson A; Kieff E
J Virol; 1990 May; 64(5):2309-18. PubMed ID: 2157887
[TBL] [Abstract][Full Text] [Related]
24. Domains of the Epstein-Barr virus nuclear antigen 2 (EBNA2) involved in the transactivation of the latent membrane protein 1 and the EBNA Cp promoters.
Sjöblom A; Nerstedt A; Jansson A; Rymo L
J Gen Virol; 1995 Nov; 76 ( Pt 11)():2669-78. PubMed ID: 7595374
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation.
Cohen JI; Wang F; Kieff E
J Virol; 1991 May; 65(5):2545-54. PubMed ID: 1850028
[TBL] [Abstract][Full Text] [Related]
26. Human p32: a coactivator for Epstein-Barr virus nuclear antigen-1-mediated transcriptional activation and possible role in viral latent cycle DNA replication.
Van Scoy S; Watakabe I; Krainer AR; Hearing J
Virology; 2000 Sep; 275(1):145-57. PubMed ID: 11017796
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus nuclear antigen 2 exerts its transactivating function through interaction with recombination signal binding protein RBP-J kappa, the homologue of Drosophila Suppressor of Hairless.
Zimber-Strobl U; Strobl LJ; Meitinger C; Hinrichs R; Sakai T; Furukawa T; Honjo T; Bornkamm GW
EMBO J; 1994 Oct; 13(20):4973-82. PubMed ID: 7957063
[TBL] [Abstract][Full Text] [Related]
28. Identification and characterization of an Epstein-Barr virus nuclear antigen 2-responsive cis element in the bidirectional promoter region of latent membrane protein and terminal protein 2 genes.
Laux G; Dugrillon F; Eckert C; Adam B; Zimber-Strobl U; Bornkamm GW
J Virol; 1994 Nov; 68(11):6947-58. PubMed ID: 7933076
[TBL] [Abstract][Full Text] [Related]
29. P32/TAP, a cellular protein that interacts with EBNA-1 of Epstein-Barr virus.
Wang Y; Finan JE; Middeldorp JM; Hayward SD
Virology; 1997 Sep; 236(1):18-29. PubMed ID: 9299613
[TBL] [Abstract][Full Text] [Related]
30. Latency pattern of Epstein-Barr virus and methylation status in Epstein-Barr virus-associated hemophagocytic syndrome.
Yoshioka M; Kikuta H; Ishiguro N; Endo R; Kobayashi K
J Med Virol; 2003 Jul; 70(3):410-9. PubMed ID: 12767005
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23.
Wang F; Gregory CD; Rowe M; Rickinson AB; Wang D; Birkenbach M; Kikutani H; Kishimoto T; Kieff E
Proc Natl Acad Sci U S A; 1987 May; 84(10):3452-6. PubMed ID: 3033649
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa.
Robertson ES; Grossman S; Johannsen E; Miller C; Lin J; Tomkinson B; Kieff E
J Virol; 1995 May; 69(5):3108-16. PubMed ID: 7707539
[TBL] [Abstract][Full Text] [Related]
33. Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1.
Kis LL; Takahara M; Nagy N; Klein G; Klein E
Immunol Lett; 2006 Apr; 104(1-2):83-8. PubMed ID: 16386314
[TBL] [Abstract][Full Text] [Related]
34. Structural, functional, and genetic comparisons of Epstein-Barr virus nuclear antigen 3A, 3B, and 3C homologues encoded by the rhesus lymphocryptovirus.
Jiang H; Cho YG; Wang F
J Virol; 2000 Jul; 74(13):5921-32. PubMed ID: 10846073
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus gene expression in nasopharyngeal carcinoma.
Young LS; Dawson CW; Clark D; Rupani H; Busson P; Tursz T; Johnson A; Rickinson AB
J Gen Virol; 1988 May; 69 ( Pt 5)():1051-65. PubMed ID: 2836550
[TBL] [Abstract][Full Text] [Related]
36. Residues 231 to 280 of the Epstein-Barr virus nuclear protein 2 are not essential for primary B-lymphocyte growth transformation.
Harada S; Yalamanchili R; Kieff E
J Virol; 1998 Dec; 72(12):9948-54. PubMed ID: 9811732
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element.
Wang F; Kikutani H; Tsang SF; Kishimoto T; Kieff E
J Virol; 1991 Aug; 65(8):4101-6. PubMed ID: 1649318
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA.
Waltzer L; Perricaudet M; Sergeant A; Manet E
J Virol; 1996 Sep; 70(9):5909-15. PubMed ID: 8709211
[TBL] [Abstract][Full Text] [Related]
39. Biochemical characterization of Epstein-Barr virus nuclear antigen 3A and 3C proteins.
Sample C; Parker B
Virology; 1994 Dec; 205(2):534-9. PubMed ID: 7975254
[TBL] [Abstract][Full Text] [Related]
40. The EBNA-2 arginine-glycine domain is critical but not essential for B-lymphocyte growth transformation; the rest of region 3 lacks essential interactive domains.
Tong X; Yalamanchili R; Harada S; Kieff E
J Virol; 1994 Oct; 68(10):6188-97. PubMed ID: 8083959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
